Reduced Covid Severity, No Deaths Likely: An Expert Decodes Covaxin’s 3rd Phase Interim Results

Posted on by

The Phase 3 study of Covaxin enlisted 25,800 participants between the age of 18-98 years, including a 10 per cent population over the age of 60.